The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial 18F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis

Journal of Nuclear Cardiology

Volumn 23, Issue 2, 2016, Pages 244-252

  Manabe, Osamu ^a   Yoshinaga, Keiichiro ^a,c   Ohira, Hiroshi ^b   Masuda, Atsuro ^a   Sato, Takahiro ^b   Tsujino, Ichizo ^b   Yamada, Asuka ^b   Oyama Manabe, Noriko ^b   Hirata, Kenji ^a   Nishimura, Masaharu ^b   Tamaki, Nagara ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

18F fluorodeoxyglucose; Cardiac sarcoidosis; free fatty acid; long fasting; positron emission tomography

Indexed keywords

FATTY ACID; FLUORODEOXYGLUCOSE F 18; HEPARIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; EVALUATION STUDY; FATTY ACID BLOOD LEVEL; FEMALE; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LOW CARBOHYDRATE DIET; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SARCOIDOSIS; BLOOD; CARDIOMYOPATHY; DIAGNOSTIC IMAGING; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY;

ADULT; AGED; CARDIOMYOPATHIES; DIET, CARBOHYDRATE-RESTRICTED; FASTING; FATTY ACIDS, NONESTERIFIED; FEMALE; FLUORODEOXYGLUCOSE F18; HEPARIN; HUMANS; MALE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; SARCOIDOSIS;

EID: 84960361441     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-015-0226-0     Document Type: Article

References (37)

1. Ishida Y, Yoshinaga K, Miyagawa M, Moroi M, Kondoh C, Kiso K, et al. Recommendations for F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology Recommendations. Ann Nucl Med 2014;28:393-403.
2. Ohira H, Tsujino I, Yoshinaga K. (1)(8)F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging 2011;38:1773-1783.
3. Schatka I, Bengel FM. Advanced imaging of cardiac sarcoidosis. J Nucl Med 2014;55:99-106.
4. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012;53:241-248.
5. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11:1305-1323.
6. Sudo S, Hattori N, Manabe O, Kato F, Mimura R, Magota K, et al. FDG PET/CT diagnostic criteria may need adjustment based on MRI to estimate the presurgical risk of extrapelvic infiltration in patients with uterine endometrial cancer. Eur J Nucl Med Mol Imaging 2015;42:676-684.
7. Hirata K, Kobayashi K, Wong KP, Manabe O, Surmak A, Tamaki N, et al. A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLoS One 2014;9:e105682.
8. Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M, et al. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol 2014;21:925-939.
9. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003;361:1111-1118.
10. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997;336:1224-1234.
11. Camici P, Ferrannini E, Opie LH. Myocardial metabolism in ischemic heart disease: Basic principles and application to imaging by positron emission tomography. Prog Cardiovasc Dis 1989;32:217-238.
12. Yoshinaga K, Tamaki N. Imaging myocardial metabolism. Curr Opin Biotechnol 2007;18:52-59.
13. Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009;16:801-810.
14. Manabe O, Ohira H, Yoshinaga K, Sato T, Klaipetch A, Oyama-Manabe N, et al. Elevated (18)F-fluorodeoxyglucose uptake in the interventricular septum is associated with atrioventricular block in patients with suspected cardiac involvement sarcoidosis. Eur J Nucl Med Mol Imaging 2013;40:1558-1566.
15. Knuuti MJ, Maki M, Yki-Jarvinen H, Voipio-Pulkki LM, Harkonen R, Haaparanta M, et al. The effect of insulin and FFA on myocardial glucose uptake. J Mol Cell Cardiol 1995;27:1359-1367.
16. Jeong J, Kong E, Chun K, Cho I. The impact of energy substrates, hormone level and subject-related factors on physiologic myocardial (18)F-FDG uptake in normal humans. Nucl Med Mol Imaging 2013;47:225-231.
17. Kreissl MC, Stout DB, Wong KP, Wu HM, Caglayan E, Ladno W, et al. Influence of dietary state and insulin on myocardial, skeletal muscle and brain [F]-fluorodeoxyglucose kinetics in mice. EJNMMI Res 2011;1:8.
18. Osborne MT, Hulten EA, Singh A, Waller AH, Bittencourt MS, Stewart GC, et al. Reduction in (1)(8)F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol 2014;21:166-174.
19. Rogers IS, Nasir K, Figueroa AL, Cury RC, Hoffmann U, Vermylen DA, et al. Feasibility of FDG imaging of the coronary arteries: Comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging 2010;3:388-397.
20. Wykrzykowska J, Lehman S, Williams G, Parker JA, Palmer MR, Varkey S, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med 2009;50:563-568.
21. Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005;26:1538-1543.
22. Kobayashi Y, Kumita S, Fukushima Y, Ishihara K, Suda M, Sakurai M. Significant suppression of myocardial (18)F-fluorodeoxyglucose uptake using 24-h carbohydrate restriction and a low-carbohydrate, high-fat diet. J Cardiol 2013;62:314-319.
23. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122S-150S.
24. Hiraga HHM, Iwai K. Guidelines for diagnosis of cardiac sarcoidosis: Study report on diffuse pulmonary diseases (in Japanese). Tokyo: The Japanese Ministry of Health and Welfare; 1993. p. 23-24.
25. Taegtmeyer H, Overturf ML. Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension 1988;11:416-426.
26. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu Rev Physiol 1974;36:413-459.
27. Romijn JA, Godfried MH, Hommes MJ, Endert E, Sauerwein HP. Decreased glucose oxidation during short-term starvation. Metabolism 1990;39:525-530.
28. Wisneski JA, Gertz EW, Neese RA, Gruenke LD, Morris DL, Craig JC. Metabolic fate of extracted glucose in normal human myocardium. J Clin Invest 1985;76:1819-1827.
29. Ferrannini E, Santoro D, Bonadonna R, Natali A, Parodi O, Camici PG. Metabolic and hemodynamic effects of insulin on human hearts. Am J Physiol 1993;264:E308-E315.
30. Morooka M, Moroi M, Uno K, Ito K, Wu J, Nakagawa T, et al. Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res 2014;4:1.
31. Cheng VY, Slomka PJ, Ahlen M, Thomson LE, Waxman AD, Berman DS. Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18F-FDG uptake during PET: A randomized controlled trial. J Nucl Cardiol 2010;17:286-291.
32. Kumar P, Patel CD, Singla S, Malhotra A. Effect of duration of fasting and diet on the myocardial uptake of F-18-2-fluoro-2-deoxyglucose (F-18 FDG) at rest. Indian J Nucl Med 2014;29:140-145.
33. Ito K, Morooka M, Okazaki O, Minaminoto R, Kubota K, Hiroe M. Efficacy of heparin loading during an 18F-FDG PET/CT examination to search for cardiac sarcoidosis activity. Clin Nucl Med 2013;38:128-130.
34. Wisneski JA, Gertz EW, Neese RA, Mayr M. Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans. J Clin Invest 1987;79:359-366.
35. Persson E. Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low molecular weight heparin fragment (Fragmin). Acta Med Scand Suppl 1988;724:1-56.
36. Gormsen LC, Christensen NL, Bendstrup E, Tolbod LP, Nielsen SS. Complete somatostatin-induced insulin suppression combined with heparin loading does not significantly suppress myocardial 18F-FDG uptake in patients with suspected cardiac sarcoidosis. J Nucl Cardiol 2013;20:1108-1115.
37. Ozguven MA, Karacalioglu AO, Ince S, Emer MO. Altered biodistribution of FDG in patients with type-2 diabetes mellitus. Ann Nucl Med 2014;28:505-511.